Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Sep 15.

Published in final edited form as: J Pharmacol Exp Ther. 1999 Dec;291(3):1113–1120.

TABLE 2.

Experimental schedules for the study of the antagonist effects of nor-BNI against systemic U50,488 and bremazocine

	Experiment 1	Experiment 2	Experiment 3

Baseline	U50,488 & bremazocine	U50,488 & bremazocine	U50,488 & bremazocine

Pretreatment conditions	i.c. nor-BNI 0.32 mg	i.c. nor-BNI 0.032 mg	s.c. nor-BNI 0.32 mg in the back
Days after nor-BNI injection	i.c. nor-BNI 0.32 mg	i.c. nor-BNI 0.032 mg	s.c. nor-BNI 0.32 mg in the back
1	U50,488	U50,488	U50,488
3	Bremazocine	Bremazocine	Bremazocine
7	U50,488	U50,488	U50,488
10	Bremazocine	Bremazocine	Bremazocine
14	U50,488	U50,488
21	U50,488	U50,488
28	Bremazocine	Bremazocine
35	U50,488	U50,488
42	Bremazocine
49	U50,488
56	Bremazocine
63	U50,488